Therapeutic Peptides to Treat Myocardial Ischemia-Reperfusion Injury

Area of Science:

• Cardiology
• Molecular Medicine
• Biochemistry

Background:

• Cardiovascular diseases (CVD), including acute myocardial infarction (AMI), are the leading cause of global mortality.
• Reperfusion therapy for AMI, while crucial, can paradoxically cause ischemia-reperfusion (IR) injury, primarily through apoptosis, leading to increased heart failure (HF) morbidity.
• Existing treatments do not address reperfusion injury, necessitating novel cardioprotective strategies, especially with rising CVD rates linked to aging, diabetes, and obesity.

Purpose of the Study:

• To review therapeutic peptides developed for treating myocardial IR injury (MIRI).
• To categorize these peptides based on their mechanisms of action, including apoptosis, necroptosis, and inflammation.
• To discuss the optimization and clinical potential of these peptide candidates for patients with AMI.

Main Methods:

• Literature review summarizing existing research on therapeutic peptides for MIRI.
• Categorization of peptides based on their interaction with cellular pathways involved in reperfusion injury.
• Analysis of the progression of therapeutic peptide candidates into clinical trials.

Main Results:

• Therapeutic peptides are emerging as a significant area of research for MIRI.
• Several peptide candidates target key pathological mechanisms of IR injury, including apoptosis, necroptosis, and inflammation.
• An increasing number of these peptides are advancing into clinical trials, indicating therapeutic potential.

Conclusions:

• Therapeutic peptides represent a promising avenue for developing novel cardioprotective strategies against MIRI.
• Targeting specific molecular pathways involved in IR injury, such as apoptosis, offers a viable treatment approach.
• Further research and clinical development are essential to translate these peptide-based therapies into effective treatments for AMI patients.